ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings results on Tuesday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.13, Briefing.com reports. During the same period last year, the firm posted ($0.30) earnings per share.

Shares of ObsEva SA (NASDAQ:OBSV) traded down 1.158% during mid-day trading on Tuesday, reaching $7.685. 21,586 shares of the company traded hands. The stock’s market capitalization is $204.60 million. The company’s 50 day moving average is $7.86 and its 200 day moving average is $9.15. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.70.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/obseva-sa-obsv-releases-quarterly-earnings-results-misses-estimates-by-0-13-eps/1492295.html.

Several research analysts have recently commented on OBSV shares. HC Wainwright started coverage on ObsEva SA in a report on Thursday, June 29th. They set a “buy” rating and a $27.00 price target on the stock. Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Credit Suisse Group AG reiterated an “outperform” rating and set a $27.00 price target on shares of ObsEva SA in a report on Tuesday, April 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. ObsEva SA has a consensus rating of “Buy” and a consensus target price of $24.00.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.